BR0209824A - Método para induzir formação neovascular e regeneração de tecido - Google Patents

Método para induzir formação neovascular e regeneração de tecido

Info

Publication number
BR0209824A
BR0209824A BR0209824-5A BRPI0209824A BR0209824A BR 0209824 A BR0209824 A BR 0209824A BR PI0209824 A BRPI0209824 A BR PI0209824A BR 0209824 A BR0209824 A BR 0209824A
Authority
BR
Brazil
Prior art keywords
tissue regeneration
administration
nucleotide sequence
neovascular formation
formation
Prior art date
Application number
BR0209824-5A
Other languages
English (en)
Inventor
Ruben Laguens
Alberto Jose Crottogini
Carlos Alberto Melo
Gustavo Leonidas Vera Janavel
Marcelo Luis Arguelles
Ricardo Horacio Pichel
Marcelo Eduardo Criscuolo
Original Assignee
Fundacion Universitaria Dr Ren
Sterrenbeld Biotechnologie North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Universitaria Dr Ren, Sterrenbeld Biotechnologie North America Inc filed Critical Fundacion Universitaria Dr Ren
Publication of BR0209824A publication Critical patent/BR0209824A/pt
Publication of BRPI0209824B1 publication Critical patent/BRPI0209824B1/pt
Publication of BRPI0209824B8 publication Critical patent/BRPI0209824B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • A61K38/1866Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA INDUZIR FORMAçãO NEOVASCULAR E REGENERAçãO DE TECIDO". A presente invenção refere-se a um método para induzir formação neovascular e regeneração de tecido em mamíferos. o método reivindicado é caracterizado pela administração de uma seq³ência de nucleotídeos que codifica o sítio ativo do fator de crescimento endotelial (VEGF) . O método induz mitose celular, miocardiogênese, arteriogênese, vasculogênese e linfangiogênese em tecidos de mamíferos. O método emprega um vetor de plasmídeo que codifica a seq³ência de nucleotídeo. A administração e realizada por rota intramiocardial.
BRPI0209824-5 2001-05-15 2002-05-13 método ex vivo ou in vitro para induzir cardiomiogênese BRPI0209824B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ARP010102313A AR027161A1 (es) 2001-05-15 2001-05-15 Metodo para inducir la proliferacion neovascular y regeneracion tisular
ARP01-01-02313 2001-05-15
PCT/US2002/014508 WO2002091995A2 (en) 2001-05-15 2002-05-13 Method to induce neovascular formation and tissue regeneration

Publications (3)

Publication Number Publication Date
BR0209824A true BR0209824A (pt) 2004-10-19
BRPI0209824B1 BRPI0209824B1 (pt) 2020-11-10
BRPI0209824B8 BRPI0209824B8 (pt) 2021-05-25

Family

ID=36129783

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0209824-5 BRPI0209824B8 (pt) 2001-05-15 2002-05-13 método ex vivo ou in vitro para induzir cardiomiogênese

Country Status (9)

Country Link
US (6) US7563777B2 (pt)
EP (2) EP2308502A1 (pt)
AR (1) AR027161A1 (pt)
AU (1) AU2002259162A1 (pt)
BR (1) BRPI0209824B8 (pt)
CA (1) CA2447343A1 (pt)
ES (1) ES2566344T3 (pt)
MX (1) MXPA03010532A (pt)
WO (1) WO2002091995A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170116A9 (en) 2002-08-22 2014-06-19 Marc S. Penn Method of treating ischemic disorders
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
EP2473196B1 (en) * 2009-08-28 2017-05-31 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
US20170100029A1 (en) * 2015-10-13 2017-04-13 The University Of North Carolina At Chapel Hill Compositions and Methods for Analyzing Collateral Density
EP3740211A4 (en) 2018-01-18 2021-04-14 Endoprotech, Inc TREATMENT OF MICROVASCULAR DISORDERS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
KR20000070572A (ko) * 1997-01-29 2000-11-25 해우슬러 에이치 월터, 리처드 에스. 카훈 혈관형성 유도용 아데노바이러스 벡터의 다중 부위 운반
CN1345247A (zh) * 1997-12-24 2002-04-17 路德维格癌症研究所 表达血管内皮生长因子d的表达载体和细胞系以及治疗黑素瘤的方法
US20010056073A1 (en) * 1998-07-21 2001-12-27 Ascher Shmulewitz Gene therapy method for revascularizing ischemic tissue
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
AU6634400A (en) * 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow

Also Published As

Publication number Publication date
CA2447343A1 (en) 2002-11-21
EP1441682A4 (en) 2007-07-11
AR027161A1 (es) 2003-03-19
US7563777B2 (en) 2009-07-21
US20160346352A1 (en) 2016-12-01
ES2566344T3 (es) 2016-04-12
AU2002259162A1 (en) 2002-11-25
US20050020522A1 (en) 2005-01-27
EP1441682B1 (en) 2016-01-20
WO2002091995A8 (en) 2004-05-06
EP2308502A1 (en) 2011-04-13
US20140341972A1 (en) 2014-11-20
EP1441682A1 (en) 2004-08-04
BRPI0209824B8 (pt) 2021-05-25
BRPI0209824B1 (pt) 2020-11-10
WO2002091995A2 (en) 2002-11-21
MXPA03010532A (es) 2005-10-05
US20090275645A1 (en) 2009-11-05
US20170252405A1 (en) 2017-09-07
US20180296641A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
BR0209824A (pt) Método para induzir formação neovascular e regeneração de tecido
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
ES2362578T3 (es) Composición que comprende la poliproteína ns3/ns4 y el polipéptido ns5b del vhc, vectores de expresión que incluyen las secuencias nucleicas correspondientes y utilización en terapéutica.
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
BR9808843A (pt) Derivados de quinolinona 1,8-anelados inibidores da farnesil transferase substituìdos com imidazóis ligados em n ou em c
BR9609006A (pt) Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
EE05680B1 (et) Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
ATE531729T1 (de) Kdr-peptide und diese enthaltende impfstoffe
BR9912448A (pt) Composto, composição farmacêutica, e, processos de indução de biossìntese de citoquina em um mamìfero, de tratamento de uma doença virótica em um mamìfero, e de tratamento de uma doença neoplásica em um mamìfero
BR0012084A (pt) Compostos, composição farmacêutica e usos dos compostos
BRPI0707543B8 (pt) composição de polipeptídeo e uso da mesma
BR0114754A (pt) Compostos não-imidazóis
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
NO20025450D0 (no) Ny farmasöytisk sammensetning
MXPA02000196A (es) Proteinas y genes anti-patogenicos de girasol y sus usos.
BR0003498A (pt) Plasmìdeo isolável de corynebacterium thermoaminogenes
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
ATE301654T1 (de) Naphthyridinderivate
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
DE3671370D1 (de) Zubereitungen zur behandlung von mycoplasmosen und bakteriellen erkrankungen bei gefluegel.
BRPI0411393A (pt) vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor
ATE536878T1 (de) Herstellung einer therapeutischen zusammensetzung
BR0211566A (pt) Aparelho e método para redução de peso eletricamente condutor
BRPI0303570B8 (pt) "construção de hgf, microrganismo transgênico, vetor e composição farmacêutico"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/04 , A01N 63/00 , C12P 21/06 , C12N 5/00 , C12N 15/00 , C12N 15/63 , C07H 21/02 , C07H 21/04

Ipc: A61K 48/00 (2006.01), C12N 15/63 (2006.01), A61P 7

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.